Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience

Leuk Res. 1991;15(4):223-7. doi: 10.1016/0145-2126(91)90124-c.

Abstract

A retrospective analysis of two ECOG adult AML trials conducted from 1976 to 1983 was carried out focusing on long term disease-free survival. This report summarizes the data on 545 patients with a minimum follow up of 7 1/2 years. The complete remission rate was 57% with an estimated cure rate of 12%. Of several prognostic variables examined only FAB type M3 (promyelocytic leukemia) was statistically significant (estimated cure rate of 33% vs 9% for other FAB subtypes).

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Transplantation
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / mortality*
  • Leukemia, Myeloid, Acute / surgery
  • Leukemia, Promyelocytic, Acute / mortality
  • Linear Models
  • Male
  • Middle Aged
  • Prognosis
  • Remission Induction
  • Retrospective Studies
  • Survival Rate
  • United States / epidemiology